Most Read Articles
6 days ago
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
Yesterday
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Roshini Claire Anthony, 5 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

5 days ago
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.

Rituximab for systemic sclerosis safely improves skin fibrosis

06 Jun 2019

Treatment with rituximab in patients with systemic sclerosis (SSc) is relatively safe and produces improvements in skin but not lung fibrosis, a study has shown.

Researchers used data from the European Scleroderma Trials and Research (EUSTAR) network and identified 254 SSc patients (median age, 51 years; 71 percent female) treated with rituximab. They assessed the safety of the drug and its effect on skin fibrosis improvement, lung fibrosis worsening and steroids use.

In the cohort, rituximab was indicated for lung involvement in 58 percent of patients and for skin involvement in 32 percent. After a median follow-up of 2 years, the majority (70 percent) of patients did not develop any side effects.

An analysis comparing the 254 rituximab-treated SSc patients with 9,575 propensity-score matched patient controls showed rituximab treatment to be associated with a higher likelihood of skin fibrosis improvement (22.7 vs 14.03 events per 100 person-years; odds ratio [OR], 2.79, 95 percent CI, 1.47–5.32; p=0.002).

On the other hand, there were no significant between-group differences observed in rates of forced vital capacity (FVC) >10 percent (OR, 1.03, 0.55–1.94; p=0.93) or in carbon monoxide diffusing capacity (DLCO) <70 percent (OR, 1.68, 0.68–4.2; p=0.27).

Compared with controls, rituximab-treated patients were more likely to stop or reduce steroids (OR, 2.34, 1.56–3.53; p<0.0001). Furthermore, patients who received mycophenolate mofetil concomitantly tended to have better outcomes than those who received rituximab alone (delta FVC: OR, 3, 0.66–5.35; p=0.012) and controls (OR, 5.22, 0.83–9.62; p=0.019).

The study was limited by its observational design, according to researchers, adding that the potential stabilization of lung fibrosis by rituximab has to be addressed in a randomized trial.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
Yesterday
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Roshini Claire Anthony, 5 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

5 days ago
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.